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Abstract
Background: Despite ongoing consumer demand and an emerging scientific evidence-base for traditional and
complementary medicine (T&CM), there remains a paucity of reliable information in standard clinical guidelines
about their use. Often T&CM interventions are not mentioned, or the recommendations arising from these
guidelines are unhelpful to end-users (i.e. patients, practitioners and policy makers). Insufficient evidence of efficacy
may be a contributing factor; however, often informative recommendations could still be made by drawing on
relevant information from other avenues. In light of this, the aim of this research was to review national and
internationally endorsed consensus statements for clinical guideline developers, and to interpret how to apply
these methods when making recommendations regarding the use of T&CM.
Method: The critical interpretive review method was used to identify and appraise relevant consensus statements
published between 1995 and 2015. The statements were identified using a purposive sampling technique until data
saturation was reached. The most recent edition of a statement was included in the analysis. The content, scope
and themes of the statements were compared and interpreted within the context of the T&CM setting; including
history, regulation, use, emerging scientific evidence-base and existing guidelines.
Results: Eight consensus statements were included in the interpretive review. Searching stopped at this stage as
no new major themes were identified. The five themes relevant to the challenges of developing T&CM guidelines
were: (1) framing the question; (2) the limitations of using an evidence hierarchy; (3) strategies for dealing with
insufficient, high quality evidence; (4) the importance of qualifying a recommendation; and (5) the need for
structured consensus development.
Conclusion: Evidence regarding safety, efficacy and cost effectiveness are not the only information required to
make recommendations for clinical guidelines. Modifying factors such as burden of disease, magnitude of effect,
current use, demand, equity and ease of integration should also be considered. Uptake of the recommendations
arising from this review are expected to result in the development of higher quality clinical guidelines that offer
greater assistance to those seeking answers about the appropriate use of T&CM.
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Background
Traditional and complementary medicine (T&CM) refers
to a conglomerate of health-related interventions and ther-
apies not usually considered mainstream by the Western
medical system. T&CM includes (but is not limited to)
naturopathy, traditional Chinese medicine, Ayurvedic
medicine, homeopathy, chiropractic, osteopathy, mas-
sage therapy, yoga and meditation. In such a multifari-
ous field with divergent training requirements, different
models of regulation, and myriad treatment options
informed by varying (and sometimes inconsistent) evi-
dence, it is not surprising there is considerable diversity
in clinical practice [1]. The impact of these inconsistent
practices on patient outcomes, patient satisfaction and
professional credibility can be significant [2].
Clinical guidelines are “systematically developed state-
ments to assist practitioner and patient decisions about
appropriate health care for specific clinical circum-
stances” [3] that aim to reduce unnecessary variations in
service delivery by informing a rational approach to the
management of patients, as well as guiding healthcare
policies. Evidence-based clinical guidelines were initially
almost solely based on evidence of efficacy and safety
[4–6]. The limitation of this approach was that it
ignored other important considerations when developing
guidelines to meet the healthcare needs of a population
[7]. Increasingly, the importance of contextual informa-
tion and qualifying statements about the burden of dis-
ease, economic impact, current use, patient values and
preferences and equity, and the need for transparency
throughout the development process have been adopted
as guideline development standards [8–10]. Despite
these standards, it is not uncommon for clinical guidelines
and health policies regarding T&CM to only consider the
evidence for safety, efficacy and cost-effectiveness, if they
are considered at all [11].
The quality of clinical guidelines continues to be a matter
of concern, hence the development of various guideline
appraisal tools such as the AGREE II [12, 13]. In the field of
T&CM, standard medical guidelines are fraught with
inconsistencies and unhelpful recommendations. For ex-
ample, reviews of guidelines endorsed by the UK National
Institute for Health Care and Excellence (NICE) or the
Scottish Intercollegiate Guidelines Network (SIGN) have
found that many lacked transparency and consistency
about the inclusion or exclusion of T&CM [14–16]. The
conclusions drawn from the available evidence often over-
estimated or underestimated potential benefits. In many
instances, even when one or more T&CM interventions
were reviewed by the guideline developers, either no
recommendations or nonspecific recommendations, such
as ‘practitioners should discuss T&CM use with their
patients’ or ‘more research is needed’ were made. General
statements provide little guidance for clinical decision
making and could be viewed as ‘holding statements’ rather
than serving any real purpose.
Given the aforementioned findings, clinical guidelines
of higher quality are urgently required to guide the safe
and rational use of T&CM in practice [17]. Indeed, there
are many instances where specific recommendations are
often needed in T&CM practice and policy. As Table 1
illustrates, the decision to appraise an intervention or
otherwise in a guideline is not always (nor should it be)
dependent on data from clinical trials.
Insufficient evidence about any intervention or prac-
tice poses significant challenges for guideline developers.
In the case of T&CM, failure to evaluate the field or
even make a recommendation when there is insufficient
evidence of efficacy may simply widen the gap between
what practitioners and users of T&CM are doing, and
what is considered best practice. Guideline developers
should always attempt to make specific, informative
recommendations about the use of T&CM [18–20]. As
Petitti et al. state:
“Decision makers do not have the luxury of waiting for
certain evidence. Even though evidence is insufficient,
the clinician must still provide advice, patients must
make choices, and policy makers must establish
policies” [21].
Further guidance on how to use all available information
and evidence for clinical decision making will help improve
the utility of clinical guidelines that consider T&CM. De-
bate continues in the T&CM field and more generally
around the appropriate use of evidence for evaluating inter-
ventions [22–24]. The objectives of this review, however,
were to identify, appraise and synthesise nationally or inter-
nationally endorsed consensus statements for clinical
Table 1 Instances where T&CM should be considered in
guideline development
1. The potential for at least modest clinical benefit where there is a large
burden of diseasea;
2. High quality traditional evidence about safety and effectiveness that
address a continuing burden of disease;
3. Cost-effective interventions that address a continuing burden
of diseasea;
4. The potential for catastrophic risks from the T&CM intervention or
its alternative;
5. Unknown benefit from a T&CM intervention that is commonly useda;
6. Inequalities of access or large unmet need;
7. High demand to integrate within conventional healthcare settings;
8. High costs relative to alternatives or vice versa;
9. Large system changes required for its introductiona; and
10. Conflict in choices between individual and societal perspectivesa.
aCriteria outlined by the World Health Organisation for prioritising guideline
development [7]
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guideline developers; and ‘interpret’ how these statements
might apply to the field of T&CM, particularly in instances
where there is low quality or inconsistent evidence regard-
ing safety, efficacy or cost-effectiveness.
Method
Study design
A critical interpretive review of consensus statements for
guideline developers was undertaken [25, 26]. The litera-
ture search and analysis of the consensus statements was
an iterative process. A sampling frame was created where
the identified consensus statements were coded and cate-
gorised into themes and subthemes on an electronic
spreadsheet. The first author then summarised the fi-
ndings for further discussion amongst the co-authors.
Numerous iterations explored how best to categorise and
interpret the themes until consensus was reached. Litera-
ture searching continued until there was data saturation
(i.e. the point at which no new major themes emerged).
Literature search & sampling
The consensus statements for guideline developers were
identified using a similar approach to that used in the in-
terpretive synthesis outlined by Dixon-Woods et.al [26].
The literature was searched from 7th April 2014 through
to 10th October 2015. A systematic literature search was
not conducted, because unlike Schünemann et.al, this re-
view was not a content analysis where all consensus state-
ments are identified to formulate a comprehensive list of
items from these statements [27]. Instead, purposive sam-
pling was used to identify statements published before the
end-date of the search that clearly addressed the research
objective. Consensus statements and publications were
first identified through the authors’ expert knowledge of
the topic. This was augmented by literature searches
on Google Scholar and PubMed. Database searches
using various sets of search terms (e.g. guidelines*,
“Practice Guidelines as Topic/standards”[Mesh], Evidence-
Based Medicine/methods[Mesh]) and search functions (e.g.
customizing Article types) were abandoned because the
results were either too broad or too narrow. Alternate
search strategies were therefore employed, such as bib-
liographic searching of previously published systematic re-
views [27], bibliographic cluster searching [28], and the use
of ‘PubMed/Similar articles’ or ‘Google Scholar/Related
articles’ functions.
Inclusion & exclusion criteria
The authors defined a consensus statement as a docu-
ment or similar resource (e.g. website) developed by an
independent panel of experts that provided systematic
guidance. In this instance, the guidance was on met-
hodologies for formulating clinical guidelines or related
health policies. Only statements endorsed by national or
international authorities and published in English were in-
cluded. Consensus statements on health policy making
were also included since clinical guidelines are used not
only to inform clinical decision making but to inform
health service delivery and public health policies. Consen-
sus statements describing how to appraise the quality of
clinical guidelines were excluded as no new themes could
be identified that were not already addressed in detail,
including the rationale, in the statements on guideline
development. Statements published from 1995 until the
end of the search date in 2015 were included. For those
with multiple iterations, only the most recent edition of a
statement was included in the analysis.
Data extraction & analysis
An interpretive approach was used to appraise and
synthesise the information [25, 26]. This was an induct-
ive process. As consensus statements and their related
publications were identified, their content was reviewed
for relevant themes applicable to the use, practice and
context of T&CM (see Table 2), and the known short-
comings of existing clinical guidelines for T&CM [14–16,
29–31]. The statements were compared for similarities
(reciprocal translational analysis) and contradictions
(refutational synthesis). Lines-of-arguments (synthesis-
ing arguments) were generated by integrating the content
and themes identified in the individual statements. The
aim was to identify overarching themes and constructs,
and then interpret how they apply to T&CM.
Results
Eight consensus statements for guideline developers met
the inclusion criteria for in-depth review; this was the
point at which data saturation was reached and no new
major themes emerged. Three of the statements were
international [7, 18–20, 32–63]; the remaining five were
national statements from Australia [64–66], Germany
[67],Scotland [68], US [21, 69–71] and UK [72–74].
The primary focus of the first seven statements (as
listed in Table 3) was the development of clinical
Table 2 Contextual information about T&CM
1. T&CM often has different regulation than biomedicine because the
interventions are considered relatively safe and/or there is a historical
precedence of use spanning hundreds, if not thousands of years [29].
2. Clinical guidelines are often uninformative regarding the use of T&CM;
and are lacking in transparency and consistency [14–16].
3. In instances of insufficient scientific evidence, information about
clinical indications and safety; patient demand and preferences; or
equity and costs may still be available [29].
4. The outcomes that users seek from T&CM do not always align with
the outcomes evaluated in clinical trials [30].
5. The ongoing demand for T&CM suggests that factors other than
scientific evidence are important and influence the decision making
process of patients and practitioners [31].
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practice guidelines for the management or prevention of
disease. These guidelines all used similar methodologies
for systematically identifying and appraising the evidence
of efficacy, safety and cost-effectiveness [7, 32, 64, 67, 68,
70, 72]. However, there were differences in the termin-
ology and categories used to summarise the evidence
and formulate recommendations. GRADE, AWMF and
the NHMRC, for example, categorised the quality of
the evidence and the strength of the recommenda-
tions [32, 66, 67]. Alternatively, NICE provided guid-
ance on the wording of phrases to reflect the strength
of the recommendations rather than using explicit grades
or categories [72]. Both the USPSTF and SIGN included
an option to make a non-specific recommendation for
instances of genuine uncertainty [68, 70].
The eighth consensus statement included in this re-
view, the SUPPORT guidelines [46] was the only state-
ment aimed solely at evidence-informed health policy
making, including decisions about healthcare services.
The SUPPORT guidelines acknowledge controlled trials
and systematic reviews as important, but in addition,
they emphasise the value of obtaining other information
and local evidence of modifying factors such as needs,
values, costs and the availability of resources. Import-
antly, they also offer guidance on preparing and using
policy briefs [53, 61].
Following a detailed analysis of the eight selected
consensus statements and their related publications, five
main themes emerged that were relevant to the chal-
lenges of developing T&CM recommendations and are
particularly relevant when there is low quality, conflict-
ing or inconsistent evidence. These were:
1. The importance of framing the question.
2. The limitations of an evidence hierarchy.
3. Methods for dealing with insufficient evidence.
4. Qualifying a recommendation.
5. Structured consensus development.
Framing the question
All eight statements provided guidance about clarifying
at the outset of the guideline development process the
Table 3 Summary of consensus statements for guideline
developers
1. Guidelines for W.H.O. guidelines [7].
A concise outline of the principles for guideline development, the
statement emphasises the importance of considering local
circumstances such as applicability of the research findings to the
population and the feasibility and opportunity costs of
implementing the guideline. Annex C provides a succinct yet
comprehensive checklist for appraising treatment guidelines.
2. GRADE Grading of Recommendations Assessment, Development and
Evaluation [18, 19, 32–44].
Endorsed by the Cochrane Collaboration and W.H.O., GRADE is an
internationally recognised system for evaluating and comparing
alternative interventions. Recommendations are graded based on the
quality of evidence (i.e. study design, bias, consistency of the results,
and precision of the overall estimates); risks and benefits; resources
used; and values and preferencesResources include the online software
GRADEproGDT for producing guidelines, Summary of Findings tables
and Evidence to Decision Frameworks [45].
3. AWMF Regelwerk/Guidance Manual and Rules for Guideline
Development [67].
The Association of the Scientific Medical Societies in Germany (AWMF)
builds on the GRADE process. It also provides explicit guidance on how
to structure consensus development, classify the strength of consensus
and manage justified dissent to formulate a transparent set of
recommendations. Accompanying statements included the DELBI
2.0 - Deutsche Leitlinien-Bewertungsinstrument/German Guideline
Appraisal Instrument.
4. NHMRC: A guide to the development, evaluation and implementation
of clinical practice guidelines [64].
The Australian National Health and Medical Council (NHMRC)
guidelines along with seven accompanying handbooks were published
from 1999 to 2003. Together they provide detailed information about
reviewing and appraising clinical, economic and socioeconomic
evidence; implementing and disseminating guidelines; and presenting
the information to consumers. Guidelines on appraising evidence and
grading recommendations were updated in 2009 and included a Body
of Evidence Matrix [65, 66]. A ‘hierarchy of evidence’ constrains the
grading of recommendations.
5. NICE: Developing NICE guidelines - The manual [72].
The National Institute for Health Care and Excellence (NICE) guidelines
manual from the United Kingdom has evolved over time. Initially
recommendations were rated according to a ‘hierarchy of evidence’ that
reflected the quality of studies. This rating was replaced in 2006–7 with
an approach that more closely aligns with GRADE. Differences to GRADE
include modifications to the economic evidence profiles and the
absence of ‘overall summary’ labels for the quality of evidence and
strength of recommendations [74].
6. SIGN 50: A Guideline Developer’s Handbook [68].
The Scottish Intercollegiate Guidelines Network (SIGN), first published
their handbook in 1999. It was modified over the years to reflect
methodological changes in appraising the evidence and grading
recommendations. A hierarchy of evidence was used from 2001 to
2012 that was discontinued in line with the SIGN’s adoption of the
GRADE process in 2013.
7. U.S. Preventive Services Task Force (USPSTF) system [69].
The system is used to assess the quality, magnitude and confidence in
the evidence about benefits and harms of an intervention and provide
a graded recommendation [70]. An analytic structured causal framework
of process and outcome is recommended to help guide the systematic
evaluation of non-RCT study designs [71]. If the problem of insufficient
evidence persists, the four “Domains of Information Pertinent to Clinical
Decision making for Preventive Services” may be used [21].
Table 3 Summary of consensus statements for guideline
developers (Continued)
8. SUPPORT Tools for evidence-informed health Policymaking (STP) [20, 46–63].
STP was written for people responsible for making decisions about
health policies and programmes and for those who support these
decision makers. The series addresses four broad areas: 1) Supporting
evidence-informed policymaking 2) Identifying needs for research
evidence in relation to three steps in policymaking processes, namely
problem clarification, options framing, and implementation planning 3)
Finding and assessing both systematic reviews and other types of
evidence to inform these steps, and 4) Going from research evidence
to decisions.
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intended scope, questions, interventions and outcomes
to be covered. The PICO process (Patient problem,
Intervention, Comparison, Outcome) was often recom-
mended to help formulate clinically relevant questions
and patient-important outcomes were increasingly
emphasised [36, 67, 68, 72].
Little guidance was provided however about methods
for systematically identify potentially relevant interven-
tions and selecting interventions for further in-depth
systematic reviews. The WHO and NICE both provided
guidance around choosing priority topics and interven-
tions [7, 72]. This included interventions that were
commonly used with unclear benefits and risks. The
NICE 2012 edition was the only consensus statement
that specifically mentioned high T&CM use by patients
for managing the problem as a reason for inclusion, and
the importance of searching databases relevant to
T&CM evidence [73].
“The effects of complementary and alternative
therapies may be addressed in the guideline if such
therapies are commonly used in the clinical area of
interest. If commonly used complementary and
alternative therapies are not to be covered in the
guideline, this should be stated clearly in the scope.”
[73].
Limitations of an evidence hierarchy
As the various recommendations for developing guide-
lines have been updated, there has been a move away from
using a ‘hierarchy of evidence’ or ‘levels of evidence’ to-
wards the GRADE approach to making recommendations.
This is due to ongoing concerns that a hierarchy can in-
appropriately encourage guideline developers and policy
makers to directly link study design to recommendation
strength, or ignore lower levels of evidence that should
also be included when grading the strength of the recom-
mendation [74]. NICE ceased using an evidence hierarchy
in 2007–8, followed by SIGN in 2012; notwithstanding,
the 2014 edition of SIGN still refers to levels of evidence
in the “Example pages from an evidence table” [68].
The Australian National Health and Medical Research
Council (NHMRC) guideline was the only included con-
sensus statement that continued to use an evidence hier-
archy as a direct constrainer on the strength of the
recommendations [66]. According to these guidelines,
the strongest recommendations, an ‘A’ or ‘B’, can only be
made if the evidence quality is also graded as an ‘A’ or
‘B’. The NHMRC does acknowledge that questions about
safety – especially for uncommon adverse events from
treatments or harms from diagnostic testing – are un-
likely to be answered through randomised controlled
trials and in such cases, consideration of lower levels of
evidence are permitted.
Dealing with insufficient evidence
GRADE and the USPSTF statements provided the most
specific advice on how to manage the challenges of
insufficient, high quality evidence. The SUPPORT state-
ment most clearly emphasised that inconclusive results
or lack of research should not be misinterpreted as
evidence of no effect. Despite insufficient evidence about
effectiveness, informed decisions can still be made about
interventions that are potentially harmful or when the
potential benefits are not worth the cost [20].
In situations of low quality evidence for an interven-
tion and a lack of confidence in the effect estimates of
the risks and benefits, the GRADE statements outlined
five instances when a strong recommendation could still
be made [18]. Table 4 is a modification of the GRADE
guidelines where the original non-T&CM examples are
replaced with examples pertinent to T&CM.
In the case of inconclusive or absent evidence from
randomised controlled trials (RCTs) and meta-analyses,
the USPSTF proposed several instances where the
assemblage of non-RCT evidence would be admissible in
clinical guidelines. The first is where an intervention is
potentially effective, there is a large burden of disease
and there is no research investigating the direct effects
of the intervention on the health outcome [71]. In this
instance, a Generic Analytic Framework (GAF) could be
constructed to answer a sequence of key questions that
form a chain of evidence about benefits and risks [71].
Recommendations can then be formulated based on
indirect evidence linking the intervention to the out-
come. For example, an intervention that demonstrates a
reduction in the incidence rate of ischaemic heart
disease (IHD) is direct evidence. When the same inter-
vention has only demonstrated an ability to lower a
person’s weight, other research must be linked to pro-
vide indirect evidence that losing weight can reduce
known IHD risk factors and the likelihood of developing
IHD. The safety, acceptability and costs of the interven-
tion are also considered. The USPSTF further recognises
that different types and quality of evidence will be
required to link the evidence.
The second instance proposed by the USPSTF for the
assemblage of non-RCT evidence is when the intervention
is not amenable to being evaluated under RCT conditions
[21]. Examples given included various behavioural inter-
ventions for substance abuse where either there is no
appropriate control for blinding, or it is impossible to pro-
vide the treatment fidelity required for an RCT because it
would eliminate the individualised, adaptive treatment
approach that is needed for success.
For instances when despite using the above two sugges-
tions there remains insufficient evidence, the USPSTF rec-
ommends structuring information around the following
four domains to explicitly present data for decision makers:
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1. Burden of suffering – the incidence and prevalence
of a condition; the degree of personal, family and
community suffering; and the burden to families,
society and health care systems.
2. Potential harm – the immediate and long-term harms
to individuals and patients from delivering an interven-
tion or service and from alternatives, including the
potential harms associated with doing nothing.
3. Cost – the direct monetary costs of a service or
intervention; the opportunity costs, such as the time,
money and resources that would be diverted to
provide an intervention with less evidence or
acceptability to patients; and the costs of
decommissioning the intervention should it then
prove to be ineffective.
4. Current practice – the potential negative
consequences (including legal) of providing a novel,
less widely used service or intervention compared to
those commonly in place; and the extra resources
that will be needed to change ingrained practice
[21]. (In the case of T&CM, this question might
also be extended to consider the consequences
of removing or restricting access to commonly
used interventions).
Both the USPSTF and SIGN included a category for
recommending the use of interventions in the research
setting only [68, 70]. The USPSTF stated that only-in-
research recommendations should be reserved for promis-
ing interventions where there is the potential to cause
significant harm or there are high costs [70]. The latter
includes interventions where there is a large component
of fixed costs that cannot be retrieved if the intervention
is withdrawn [21]. Conversely, GRADE did not provide an
only-in-research category. Such a recommendation is pos-
sible however, if the following three conditions are met:
1. There is genuine uncertainty from the existing evidence;
2. Further research is very likely to remove or reduce
this uncertainty; and
3. The cost of further research is deemed to be good
value [19].
Qualifying a recommendation
There was general consensus across all statements that
an evidence-based guideline is unhelpful if it fails to pro-
vide information about modifying factors. Contextual
information about the burden of disease and available
interventions; generalisability and applicability to popu-
lation groups; direct and indirect costs; demand, accessi-
bility and equity; and the values and preferences of
patients and providers is increasingly being used to help
select interventions, identify relevant outcomes for ap-
praising the evidence, provide information about benefits
and risks, and to qualify recommendations [4–7, 72].
High quality evidence in support of these modifying
factors may justify upgrading or downgrading a recom-
mendation [18]. For example, patients may consider the
most effective intervention to be unacceptable due to
their personal tolerance for risk, or other personal values
such as a preference for natural therapies. In the case of
healthcare providers and policy makers, equity, costs
and current service provision are likely to be influencing
factors. An intervention with small clinical impact (effect
size) that is widely used or readily available, may be
preferred to an intervention with large clinical impact
that is significantly more expensive or requires substan-
tial system changes to integrate into practice. That
patients or policy makers make different choices based
on preferences, values and costs, are reasons why an
intervention with high quality scientific evidence of
efficacy may still be downgraded to a weak recommen-
dation and vice versa [18, 19].
Table 4 The application of the GRADE “Paradigmatic situations
in which a strong recommendation may be warranted despite low
or very low confidence in effect estimates” for T&CMa
1. When low quality evidence suggests benefit in a life-threatening situ-
ation (evidence regarding harms can be low or high)
e.g. Very low quality evidence for intravenous silibinin for life-threatening
amatoxin mushroom poisoning [91, 92], or intravenous ascorbate for
life-threatening viral infections [93, 94]. Recommend to use if there are
no alternate proven interventions.
2. When low quality evidence suggests benefit and high quality
evidence suggests harm or a very high cost
e.g. Low quality evidence that intravenous ascorbate improves quality
of life and reduces chemotherapy toxicity in cancer treatment, and high
quality of evidence of very high costs compared to oral ascorbate [95].
If there are significant opportunity costs to the patient, recommend
not to use intravenous.
3. When low quality evidence suggests equivalence of two alternatives,
but high quality evidence of less harm for one of the competing
alternatives
e.g. Low quality evidence of equivalence of glucosamine and non-steroidal
anti-inflammatory drugs (NSAIDS) for the long-term symptomatic
management of osteoarthritis; but high quality evidence of increased
gastrointestinal and cardiovascular risks for NSAIDs only [96, 97].
Recommend glucosamine as first-line treatment, especially for
patients with a higher risk of complications from NSAIDs.
4. When high quality evidence suggests equivalence of two alternatives
and low quality evidence suggests harm in one alternative
e.g. High quality equivalence of certain proprietary extracts of St. John’s
Wort and selective serotonin reuptake inhibitors (SSRIs) for depression; and
low quality evidence of a higher risk of suicide with SSRIs [98–100]. If
these certain proprietary St. John’s Wort extracts are available and
affordable, then recommend as first-line treatment before an SSRI.
5. When high quality evidence suggests modest benefits and low/very
low quality evidence suggests the possibility of catastrophic harm
e.g. High quality evidence of modest benefit from peri-operative use of fish
oil for elective Coronary Artery Bypass Surgery; and low quality evidence
for catastrophic haemorrhage [80–82]. Recommend not to cancel CAB
surgery if the patient has taken fish oil pre-operatively.
aModified from GRADE where non-TC&M examples were presented [18]
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The NHMRC proposed a system that includes the
grading of modifying factors [65, 66]. The NHMRC
Evidence Matrix grades the evidence for safety, efficacy,
cost-effectiveness, consistency of results, clinical impact,
the generalisability of the evidence and its applicability
to the Australian healthcare setting. Evidence about
other important modifying factors however, such as
patient and provider preferences were not included.
Only-in-research recommendations also require quali-
fication. GRADE for example actively discouraged blan-
ket statements recommending further scientific research
[18]. Instead, such recommendations should include
justification of the need for further research and detail
the research questions with particular attention given to
patient-important outcomes [19, 21].
Structured consensus development
All eight statements in this review emphasised that mem-
bership of a guideline development committee should
represent the relevant stakeholders. AWMF 2.0 was the
only statement however to recommend and outline scien-
tifically sound formal consensus methods to promote
transparency and resolve conflicts arising from differences
of opinion [67]. Given the complexity of the decision-
making process that necessitates sourcing and appraising
all the information, non-objective personal and profes-
sional biases are likely to emerge when selecting interven-
tions and outcomes, appraising modifying factors, and
formulating recommendations. Standardised methods
such as the Nominal Group Process, the Structured
Consensus Conference and the Delphi Technique were
recommended. The ultimate aim is to improve the trans-
parency, quality, reproducibility and acceptability of the
recommendations [67].
Discussion
This is first known review to synthesise the content and
themes of national and international consensus state-
ments for developing clinical and health policy guide-
lines and to interpret these through the lens of T&CM.
Given the influence of the evidence-based medicine
movement on clinical practice, education and health pol-
icy, it is not surprising that the majority of statements
reviewed in this paper provided detailed guidance on
how to systematically identify and appraise evidence of
efficacy [27]. The limitations of using a didactic 'recipe
book' approach when formulating recommendations was
increasingly being recognised; particularly the limitations
of using an evidence hierarchy and the importance of
modifying factors [24, 74]. The USPSTF statements pro-
vided the clearest guidance and strategies for dealing
with insufficient evidence.
Notwithstanding alternate, more pragmatic approaches
to evidence appraisal such as those proposed by the
USPSTF, the paucity and heterogeneity of scientific
evidence for many T&CM interventions remains a sig-
nificant challenge to guideline developers. It is important
not to imply that inconsistent evidence or an absence of
evidence means there is evidence of no effect [20]. In
these instances the general consensus was that guide-
lines should still attempt to make specific recommenda-
tions or at least offer some information to help guide
decisions [18, 20, 21]. Table 4 lists the paradigmatic
circumstances proposed by GRADE where a strong
recommendation could be made despite low quality evi-
dence [18]. Guideline developers should be mindful of
these instances and not automatically default to a rec-
ommendation not to use an intervention based solely on
low quality scientific evidence regarding efficacy [18, 21].
The early use of an evidence hierarchy that places the
RCT and meta-analyses at the pinnacle may help explain
the ad-hoc inclusion and appraisal of T&CM in clinical
guidelines, especially older guidelines [16]. If higher levels
of evidence are lacking and lower levels of evidence are
discounted with no qualifying statements, gaps in the
evidence review are likely to occur and an intervention
overlooked [74]. The guidelines may then default to non-
informative statements and recommendations, as was
found to be the case in the reviews of UK clinical guide-
lines [16]. Consistent with international standards, bodies
such as the Australian NHMRC should cease endorsing
the use of ‘levels of evidence’ as a direct constrainer of
ensuing recommendations and instead make greater
use of qualifying statements that consider important
modifying factors, including those relevant to patients
and practitioners.
The USPSTF suggested a number of instances when
the double-blind RCT is not the most appropriate study
design [18–21]. Although the specific components of a
T&CM intervention may be amenable to assessment
using an RCT design, there are many instances where
this is not appropriate [75]. For example, for some
T&CM interventions, finding an adequate control may
be difficult or impossible; and for others, treatment fidel-
ity would be lost due to the individualised, multifaceted
approach of the therapy or the complexity of the study
outcomes that are multiple and holistic, with some being
immediate and others delayed [76, 77].
A potential T&CM example for the assemblage of
admissible non-RCT evidence is acupuncture for depres-
sion [21, 71]. Depression is an illness where there is a
large burden of disease and there is growing pragmatic
evidence of effectiveness, but weak or conflicting evi-
dence from double-blind RCTs about the efficacy of
acupuncture [78]. The challenge with finding a suitable
control for acupuncture, as well as the individualised
nature of the intervention, may explain the mixed results
from efficacy (explanatory) trials compared to the more
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consistent positive results from effectiveness (pragmatic)
trials [79]. In cases such as this, it may even be justified
to give a lower weighting to the quality score of study
designs that use a non-individualised treatment protocol
or an inappropriate control.
Due to the paucity of a large body of high quality
evidence regarding efficacy for many T&CM interventions,
a common recommendation from systematic reviews and
clinical guidelines is to make a general call for further re-
search. This is unhelpful to clinicians and patients who
need immediate guidance and should only be made if the
research is warranted [19, 21]. A recommendation for fur-
ther research should only be made for interventions where
there is true uncertainty about risks and benefits; especially
if there are large direct costs or opportunity costs, or there
is the potential for large benefit from wider, more equitable
use [20]. For example, along with the strong recommenda-
tion not to cancel coronary artery bypass surgery if a
patient has taken fish oil preoperatively (see Table 4:
example 5) [80–82]; recommendations for further research
are justified. Treatment duration and doses of EPA and
DHA requires further clarification. There is potential for
different populations to disproportionally benefit (e.g.
socioeconomic, ethnic, or other groups with specific cardio-
vascular risk factors). Economic evaluations are also war-
ranted since the cost of fish oil, even with only
modest clinical benefit, may be cost-effective com-
pared to the cost of surgical complications; and
health inequalities are a concern since patients com-
monly pay 100% out-of-pocket to use fish oil.
Including modifying factors when qualifying recom-
mendations enhances their relevance to different clinical
scenarios and populations [18, 21]. The diverse and
potentially conflicting information about efficacy and
relevant modifying factors is particularly challenging for
guideline developers. Modifying factors can be used for
example to upgrade or downgrade the strength of a
recommendation independent of the quality of the
evidence [18, 19]. This point is particularly relevant to
T&CM interventions where there is insufficient high
quality scientific evidence regarding efficacy and effect-
iveness. In these instances, high quality evidence may
still be available about the burden of disease; risks of
alternate therapies; direct and indirect costs; demand,
access, affordability and equity; generalisability and ap-
plicability of the intervention to specific population
groups; patient and provider values and preferences; and
implementation and feasibility [7–10, 27, 32, 83]. It is
therefore inappropriate to limit systematic literature
reviews for informing guideline development only to
questions about safety, efficacy and cost-effectiveness.
To elaborate, there is high quality evidence that
hormone replacement therapy (HRT) is effective for
managing menopausal symptoms; however, there is also
high quality evidence about the risks of HRT. [84, 85] By
contrast, there is conflicting evidence about the efficacy
of Black Cohosh for managing menopausal symptoms and
very low quality evidence questioning its safety [86, 87].
There is also high quality evidence that some women
would prefer to use potentially less effective natural
approaches to manage these non-life-threatening symp-
toms, of which herbs such as Black Cohosh are amongst
the most popular choices [88–90]. Although many clinical
guidelines qualify the recommendation to use HRT with a
statement about assessing the risks and benefits of
hormone use for an individual patient, most fail to make
any qualifying statements about known patient prefer-
ences to use T&CM, its comparative safety, and the direct
costs and opportunity costs of first trialling a potentially
less efficacious intervention [90].
The inconsistencies regarding the inclusion of T&CM
and recommendations made about their use in clinical
guidelines calls for a more transparent and systematic ap-
proach to guideline development. Even formal methods
for consensus development such as those outlined in
AWMF [67] will be prone to bias if the expert committee
for example, brainstorms or uses other non-systematic
methods to select comparison interventions. The scope,
interventions and outcomes will then likely reflect the
experience and knowledge of the members of the com-
mittee, or other biases such as only considering inter-
ventions that are thought to have high quality evidence
and worthy of consideration. As WHO and NICE
highlighted, amongst other reasons (see Table 1)
T&CM should be considered if they are commonly
used in the clinical context [7, 73], irrespective of the
quality of evidence about their benefits and risks [7].
Conclusion & recommendations
This interpretive review has considered, for the first
time, the usefulness of directives for developing guide-
lines and recommendations regarding T&CM practice
and policy. Like many areas of healthcare, insufficient
evidence about efficacy poses significant challenges to
guideline developers, which in the field of T&CM has
contributed towards insufficient and inconsistent recom-
mendations. The emerging and heterogeneous evidence-
base for many T&CM interventions necessitates a range
of methodologies to ensure the systematic selection of
interventions and consideration of modifying factors
when formulating and qualifying recommendations. In
light of these issues and the high demand for T&CM, we
behove guideline developers to consider T&CM from a
number of perspectives when appraising the evidence,
and to make clinically useful and specific recommenda-
tions regarding their use.
Specifically, guideline developers should cease endors-
ing an evidence hierarchy as a direct constrainer of
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recommendations. Strict use of the levels of evidence
runs the risk of inappropriately linking the quality of the
evidence for efficacy directly to the strength of the
recommendation, whilst ignoring admissible non-RCT
evidence and important modifying factors. In instances
of very low quality or equivocal evidence of efficacy,
guideline developers must consider the paradigmatic sit-
uations where nonetheless a strong recommendation
can be made. Failing this, broader contextual informa-
tion is often available for T&CM even when there is low
quality scientific evidence regarding efficacy. Information
about modifying factors should be presented to facilitate
informed decision making and improve clinical rele-
vance. Finally, greater attention must be given to adopt-
ing a systematic and transparent approach to the entire
development process, including the selection of com-
parative interventions and patient relevant outcomes.
The uptake of these recommendations is expected to
result in higher quality clinical guidelines that offer
greater assistance to those seeking answers about the
appropriate use of T&CM.
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